full list rate price target
earn chang report pleas see
tabl page
anim health impact trend
anim health firm one true global franchis coverag
livestock segment critic global food protein demand coupl
steadi spend petcar intrins resili underpin defens
flag one top defens stock refer quantum solac
stay confid group abil outperform cogniz nt
headwind busi model esp companion anim henc lower
estim anim health stock reiter ow rate
highlight follow key updat post convers
livestock demand continu resili see retail
stock off-set declin open restaur due lockdown across countri
companion anim spend steadi even recess pet owner continu
spend pet major differ travel restrict limit vet visit
like impact well visit antibiot inject vaccin number
antech diagnost studi give clear pet regard line
studi conclud current evid cat dog infect covid-
view posit pet petcar also relief pet owner link
fda announc vet posit simparica trio allow vet examin
anim prescrib drug video sustain social distanc telemedicin
significantli posit especi new product launch like simparica trio link
field forc updat compani comment rep activ engag
vet via phone videoconfer less common
optim rep even abl make call lieu travel
suppli chain inventori reassur comment adequ
inventori month month resp ensur steadi product still
abl get product us packag vet still excit
manufactur steadi almost intact global manufactur
significantli impact likewis across site includ franc uk
rise altern channel needless say expect altern channel pick
like chewi amazon see greater traffic current new rx
latest china reassur updat manufactur mostli resum though
case like elan wuxi facil may back capac yet
happen recess neither list
anim health industri highli resili continu grow flat low singl
durat
lockdowns/restrict econom impact
uncertainti
despit lower estim multipl compress expect
outperform factor current uncertainti lower estim
coverag mostli come companion anim side rang
said believ stock continu outperform stay ow
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
valuat methodolog risk
valuat methodolog valu stand-alon without bayer ep yield price target
risk may imped achiev barclay research valuat price downsid greater global uncertainti
volatil fx headwind intern revenu greater-than-expect gener threat rumensin sale lose
exclus global slowdown protein consumpt driven chang tast declin popul growth african swine flu
epidem worsen integr risk post bayer closur upsid global acceler protein consumpt trend driven
chang tast declin popul growth greater expect oper margin improv
valuat methodolog pt base ntm price-to-earnings multipl
risk may imped achiev barclay research valuat price risk ew thesi includ upsid
stronger-than-expect global growth particularli emerg market asf recoveri faster expect downsid lower
expect intern expans margin expans osprey integr slower expect approv regulatori agenc
valuat methodolog pt base price-to-earnings multipl appli ep
risk may imped achiev barclay research valuat price risk ow thesi includ weak
integr abaxi delay launch simparicatrio greater anticip competit impact
ow pt
overal highlight experi past econom downtown grow
better lsd-msd anim health industri averag overal compani
believ suppli chain stabl manufactur run
believ month inventori hand instruct salesforc
continu activ engag veterinarian practic remot lower
estim primarili companion anim segment factor logist challeng
disrupt busi model uncertainti around durat current scenario
decreas pt base lower pe multipl
focu execut simparica trio launch
focu execut simparica trio launch us origin expect mid-
to-lat april follow approv trio avail strength dog
puppi eight week age older weigh least lb discuss
outlook- growth see paw ow estim
puppi annual receiv medic provid opportun
expand market
forecast trio franchis garner sale overtak apoquel
cornerston companion anim expect trio growth driven first-mov
advantag current futur competit landscap look benign see potenti
market share gain market expans us rise compliance/dur
age indic ex-u potenti eu canada market reson
prefer global exposur
ow pt
overal believ strong posit manufactur run high
confid plan execut believ month inventori
hand note expedit shipment via air travel use ship
sea compani feel good suppli chain meet upcom launch
manag expect china turn corner believ vet
clinic run lower estim factor logist challeng
disrupt busi model uncertainti around durat current scenario
decreas pt base lower pe multipl
manag withdrew previous announc revenu ep guidanc due
heighten volatil fx rate dynam anim protein market declin veterinari
clinic visit rise altern channel includ e-commerce dtc prior
guidanc issu includ core revenu repres roughli flat
growth adj ep compani expect give updat
call may
acquisit bayer ah continu track closur
expect delay merger bayer anim health anticip close
compani note regulatori bodi final review may
capabl work remot includ ftc built extra time
timelin believ current scenario highlight import enhanc
addit highlight term acquisit collar
maximum number share substanti rais financ term
loan revolv addit announc divestur fund
cash portion offer bayer anim health busi combin
secondari equiti offer share equiti unit total gross proce
around substanti rais financ requir
anim health defens sector reason remain
livestock companion anim segment anim healthcar sector
defens market show trait consum stapl steadi spend declin econom
downturn rel lower sector mostli out-of-pocket cash pay fast-
grow base emerg market
livestock driver rise protein consumpt multi-decad trend
livestock side econom growth-fuel multi-decad grow global demand
protein led emerg market includ china india south east asian
latin american countri see rise protein consumpt
increas global protein consumpt driven em
em popul nearli doubl sinc
pet driver steadi growth pet pet spend
us one highest rate pet ownership global per american pet
product associ appa us household pet
largest spend pet typic dog cat owner largest categori
spend board food health expect healthcar spend grow steadili
driven newer launch address previous unmet pet need
cattl chicken swine consumt mm dmem barclay specialti pharmaceut
rise number us household own pet
rise number pet us
veterinari cost increas drove pet industri spend
overweight ow driven
new launch companion anim health
greater thrust toward biolog drug
unmet need chronic diseas pet also
expect continu effici alloc
capit done past value-ad
strong global growth faster anticip margin
expans earlier launch symparica trio valu
weak integr abaxi delay launch
symparica trio greater anticip competit
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight ow base improv
revenu outlook launch pick esp ca
segment introduc new market
expect opm improv acquisit
bayer ah provid revenu advantag improv
competit advantag gener next set
synergi expect stock trade light
near term uncertain environ
base faster anticip achiev
opm leverag goal achiev
stronger environ pet care recoveri
livestock segment greater synergi multipl
like expand anoth case
base poor integr bayer ah busi
post closur weaker global growth translat
weaken ca outlook failur realiz oper
effici factor multipl compress
scenario
equal weight think
delay benefit asf recoveri peer
adapt registr regulatori chang around
antibiot expect gradual recoveri dairi
emerg market asf recoveri faster
lower-than-expect intern expans
margin expans osprey integr slower
expect approv regulatori agenc
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
quantum solac turbul time
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
